Author | Timothy S. Pardee, MD | OncLive

Author | Timothy S. Pardee, MD

Articles

Dr. Pardee on CPI-613 for Patients With R/R AML

September 11, 2014

Video

Timothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

Dr. Pardee Provides an Update on CPI-613

December 20, 2013

Video

Timothy S. Pardee, MD, describes a phase I study of the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies.

Dr. Pardee on CPI-613 in Hematologic Malignancies

July 10, 2013

Video

Timothy S. Pardee, MD, describes a phase I trial looking at the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

x